Table 2.
Characteristics of Reported Cases of TAFRO Syndrome Complicated with DIC.
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Our case | |
|---|---|---|---|---|---|
| Age/Sex | 57/F | 49/M | 56/F | 78/F | 38/M |
| Platelet (103/μL) | 13 | 10 | 44 | <50 | 34 |
| PT-INR | 1.44 | 1.36 | 0.94 | 1.17 | 1.33 |
| Fibrinogen (mg/dL) | 461 | 777 | 532 | 543 | 654 |
| FDP (μg/mL) | 32.1 | 22.3 | 42.2 | 51.3 | 72.3 |
| Treatment | GC+CHOEP | GC+IVIG | GC+CyA | GC+TCZ | GC+CyA+TCZ+rTM |
| Outcome | died | died | remission | died | remission |
| References | 3 | 4 | 4 | 5 |
PT-INR: prothrombin time-international normalized ratio, FDP: fibrin/fibrinogen degradation products, GC:glucocorticoid, CHOEP: cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisolone, IVIG: intravenous immunoglobulin, CyA: cyclosporin A, TCZ: tocilizumab, rTM: recombinant thrombomodulin